Best of ASCO - 2014 Annual Meeting

 

Welcome

Attend this session at the
2019 ASCO Annual Meeting!


Session: Melanoma/Skin Cancers

Type: Poster Session

Time: Monday June 3, 1:15 PM to 4:15 PM

Location: Hall A

Prediction of distant melanoma recurrence from primary tumor digital H&E images using deep learning.

Sub-category:
Biomarkers/Epidemiology/Outcomes

Category:
Melanoma/Skin Cancers

Meeting:
2019 ASCO Annual Meeting

Abstract No:
9577

Poster Board Number:
Poster Session (Board #148)

Citation:
J Clin Oncol 37, 2019 (suppl; abstr 9577)

Author(s): Eric Robinson, Prathamesh M. Kulkarni, Jaya Sarin Pradhan, Robyn Denise Gartrell, Chen Yang, Emanuelle M. Rizk, Balazs Acs, Bethany Rohr, Robert Phelps, Tammie Ferringer, Basil Horst, David L. Rimm, Jing Wang, Yvonne M. Saenger; New York University Department of Anesthesiology, Perioperative Care and Pain Medicine, New York, NY; New York University Department of Psychiatry, New York, NY; Columbia University Medical Center, New York, NY; Columbia University Irving Medical Center, New York, NY; Jiaotong University School of Medicine, Shanghai, China; Yale School of Medicine, New Haven, CT; Department of Pathology, Geisinger Health Systems, Danville, PA; Mount Sinai School of Medicine, New York, NY; Vancouver General Hospital, University of British Columbia, Vancouver, BC, Canada

Abstract Disclosures

Abstract:

Background: Patients with resected melanoma are at high risk for systemic recurrence. Quantifying the risk of recurrence can help identify the need for adjuvant immunotherapies, and accelerate the acquisition of survival statistics in clinical trials. Methods: 75 patients with stages I, II, and III melanoma seen at Columbia University Medical Center between 2001 and 2014 and The Icahn School of Medicine at Mount Sinai between 2000 and 2010 were included based on availability of tissue and 24 months of clinical follow-up. Images were scanned into tiff files (Aperio Biosystems). Deep neural net (DNN) architecture was designed consisting of convolutional and recurrent neural networks (CNN, RNN). Using QuPath open source software for nuclear segmentation and cell classification, we generated cell location, density, and clustering features to identify tissue areas for training of network parameters. DNN analyzes image and feature information locally within an H&E image, generating a prediction vote per region, and votes are averaged. Results: The model was validated on two independent external sets of stage I-III primary melanomas. Cohort 1 (Yale Medical Center), had n = 86 patients, of whom 49 were alive or had no evidence of disease at death (no DMR) and 37 died from melanoma. The second set, Cohort 2 (Geisnger Health Systems), had n = 29 patients, 15 without DMR and 14 with DMR. Prediction scores correlated with DMR status in both sets (AUC = 0.94 and 0.77 for Cohorts 1 and 2, respectively). A multivariable Cox proportional hazard model showed DNN recurrence prediction to be an independent prognostic factor for both Cohort 1 (HR = 2.54, 95% CI: 1.54-4.19, p = .0004***) and Cohort 2 (HR = 8.43, 95% CI: 2.58-27.51, p = .001**). Conclusions: We designed a DNN for quantitative prediction of melanoma recurrence from a H&E stained tissue. The prediction score warrants further study in larger patient cohorts and may constitute a novel digital pathology tool for the selection of melanoma patients for adjuvant immunotherapy.

Outcome characteristicsColumbiaSinaiYaleGeisinger
Patient follow-up (months)
Median, n (range)63.5 (5-173)29 (6-122)71.2 (1-456)76 (9-140)
DSS (months), n (%)
Alive or NED at death52 (78.8)3 (30)53 (57.6)19 (65.5)
Dead with melanoma14 (21.2)7 (70)39 (42.4)7 (24.1)
Unknown cause of death0 (0)0 (0)0 (0)3 (10.3)

 
Other Abstracts in this Sub-Category:

 

1. Serum IL-6 and CRP as prognostic factors in melanoma patients receiving single agent and combination checkpoint inhibition.

Meeting: 2019 ASCO Annual Meeting Abstract No: 100 First Author: Jeffrey S. Weber
Category: Melanoma/Skin Cancers - Biomarkers/Epidemiology/Outcomes

 

2. Impact of body composition on outcomes from anti-programmed death-1 (PD-1) treatment.

Meeting: 2019 ASCO Annual Meeting Abstract No: 9516 First Author: Arissa Young
Category: Melanoma/Skin Cancers - Biomarkers/Epidemiology/Outcomes

 

3. Circulating PD-L1-exosomes to monitor tumor response in melanoma patients.

Meeting: 2019 ASCO Annual Meeting Abstract No: 9517 First Author: Charlee Nardin
Category: Melanoma/Skin Cancers - Biomarkers/Epidemiology/Outcomes

 

More...